Recent News

• 10.29.2026 - ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES
• 10.08.2026 - Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
• 10.02.2026 - Addex Therapeutics Announces Executive Management Changes
• 09.28.2026 - Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
• 09.25.2026 - Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
• 09.24.2026 - Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
• 08.26.2026 - ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
• 07.08.2026 - Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
• 06.30.2026 - Addex Shareholders Approve All Resolutions at Annual General Meeting
• 06.25.2026 - Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Recent Filings

• 10.29.2026 - EX-99.1 EX-99.1
• 10.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.08.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.08.2026 - EX-99.1 EX-99.1
• 10.02.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.02.2026 - EX-99.1 EX-99.1
• 09.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.28.2026 - EX-99.1 EX-99.1
• 09.25.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.25.2026 - EX-99.1 EX-99.1